SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE

被引：0
|
作者：
Stringer, R. [1 ]
Rider, D. T. [2 ]
Newman, D. J. [2 ]
Grace, D. R. [2 ]
机构：
[1] Brighton & Sussex Med Sch, Brighton, E Sussex, England
[2] East Sussex Healthcare NHS Trust, Eastbourne, England
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1835
引用
收藏
页码：725 / 726
页数：2
相关论文
共 50 条
  • [1] Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
    Nishihori, Taiga
    Perkins, Janelle
    Mishra, Asmita
    Komrokji, Rami
    Kim, Jongphil
    Kharfan-Dabaja, Mohamed A.
    Perez, Lia
    Lancet, Jeffrey
    Fernandez, Hugo
    List, Alan
    Anasetti, Claudio
    Field, Teresa
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) : 776 - 780
  • [2] 5-azacitidine treatment for imminent relapse in patients with high-risk myelodysplastic syndromes or acute myeloid leukaemia after allogeneic peripheral blood stem cell transplantation
    Platzbecker, U.
    Radke, J.
    Kiani, A.
    von Bonin, M.
    Mohr, B.
    Oelschlaegel, U.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S81 - S81
  • [3] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
    Edlin, R.
    Connock, M.
    Tubeuf, S.
    Round, J.
    Fry-Smith, A.
    Hyde, C.
    Greenheld, W.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 69 - 74
  • [4] Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia
    Schneider, T.
    Narayanan, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 63 - 63
  • [5] EXPERIENCE WITH THE USE OF 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW/INTERMEDIATE RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Perez Dolores, Subira
    Maqueda Cristina, Fernandez
    Ramo Alejandro, Vazquez
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 152 - 152
  • [6] A Single Centre Experience of Azacitidine in Acute Myeloid Leukaemia
    Grech, M.
    Savona, S. Borg
    Sultana, E.
    Camilleri, D. J.
    Gatt, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 156 - 156
  • [7] EXPERIENCE WITH 5-AZACITIDINE IN PATIENTS DIAGNOSED BY MYELODYSPLASTIC SYNDROMES OF INTERMEDIATE 2/HIGH RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Ramo Alejandro, Vazquez
    Maqueda Cristina, Fernandez
    Garcia Helga, Guillen
    Perez Dolores, Subira
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 341 - 341
  • [8] RESPONSE TO 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASIC SYNDROME, CHRONIC MYELOMONOCYTIC LEUKEMIA, AND ACUTE MYELOID LEUKEMIA WITH HIGH-RISK GENETICS
    Perez Ortega, L.
    Falantes Gonzalez, J. F.
    Moya Arnau, M.
    Perez Simon, J. A.
    HAEMATOLOGICA, 2019, 104 : 293 - 294
  • [9] FLOW CYTOMETRY PREDICTS TREATMENT OUTCOME IN INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH 5-AZACITIDINE
    Alhan, C.
    Westers, T.
    Cali, C.
    Eeltink, C.
    Ossenkoppele, G.
    van de Loosdrecht, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 379 - 380
  • [10] SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATMENT WITH 5-AZACITIDINE: EXPERIENCE OF A CENTER
    Busnego, M. T.
    Sanchez, A.
    Notario, C.
    Cabello, A.
    Oliva, A.
    Brena, J.
    Alberich, M. P.
    Gonzalez, H.
    Marrero, C.
    Rios, P.
    Figueroa, A.
    Hernanz, N.
    Rios, M.
    Leon, A.
    Hernandez, P.
    Hillebrand, P.
    Uribe, L.
    Mesa, M. C.
    HAEMATOLOGICA, 2019, 104 : 424 - 424
12345